Valsartan is used clinical for receptor antagonist of angiotensin AT1, has good effect to the different degree of hypertension patients who used other antihypertensive without efficacy , is a new generation of highly efficient antihypertensive .
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium.
Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.
Valsartan is an angiotensin II receptor antagonistwith particularly high affinity for the type I (AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure. In the U.S., valsartan is indicated for treatment of high blood pressure, congestive heart failure (CHF), or post-myocardial infarction (MI) .
Manana orinasa avo lenta maro miaraka amin'ny fiaraha-miasa lalina, izay afaka manome anao vokatra avo lenta sy ny vidiny mifaninana. Ary afaka manome fihenam-bidy ho an'ny fividianana betsaka ihany koa izahay.Ary miara-miasa amin'ny orinasa mpitatitra entana matihanina maro izahay, afaka manatitra vokatra soa aman-tsara sy milamina amin'ny tananao. Delivery fotoana dia tokony ho 3-20 andro aorian'ny fanamafisana ny fandoavam-bola.
zavatra | Test Standard | Testing Result | |
Bika Aman 'endrika | Powder | mifanaraka | |
Color | Vovoka fotsy | mifanaraka | |
Particle Size | 100% pass 80 mesh | mifanaraka | |
Oder | Characteristic | mifanaraka | |
Taste | Characteristic | mifanaraka | |
Fatiantoka amin'ny fanamainana | ≤5.0% | 2.20% | |
Residue on Ignition | ≤0.1% | 0.05% | |
Residual acetone | ≤0.1% | mifanaraka | |
Residual Ethanol | ≤0.5% | mifanaraka | |
Heave Mentals | ≤10ppm | mifanaraka | |
Na | ≤0.1% | <0.1% | |
Pb | ≤3 ppm | mifanaraka | |
Total Plate | <1000CFU/g | mifanaraka | |
Yeast & Mold | <100 CFU /g | mifanaraka | |
E. Coli | ratsy | mifanaraka | |
Salmonella | ratsy | mifanaraka | |
Conclusion: Conform with USP Standard |
1. Orinasa ve ianao sa orinasa mpivarotra?
Izahay dia compnay mampiditra ny indostria sy ny varotra, manome serivisy tokana. Azo ekena ny OEM.
2. Manome santionany ve ianao? Maimaimpoana ve sa fanampiny?
Santionany maimaim-poana.Ny sandan'ny entana santionany dia mila aloa eo anilanao.
3. Manana taratasy fanamarinana mifandraika amin'ny fanaraha-maso kalitao ve ianao?
ISO 9001: 2008 fanamarinana mba hiantohana ny kalitao.
4. Inona no tokony homeko mba hahazoana teny nindramina?
Pls ampahafantaro anay ny karazana vokatra ilainao, ny habetsaky ny baiko, ny adiresy ary ny fepetra takiana manokana.
5. Inona no fomba fandoavam-bola tianao? Karazana fepetra inona no ekena?
Fepetra fanaterana ekena: FOB, CFR, CIF, EXW;
Vola fandoavana ekena:USD;
Accepted Payment Type: T/T,Western Union; Paypal,BTC
Fiteny ampiasaina: Anglisy.
Ny sokajy vokatra